Relievant Medsystems, a privately held medical device company that has developed the Intracept® Procedure, a minimally invasive and clinically proven approach for the treatment of chronic low back pain, announced today the appointment of Christopher Geyen as Chief Financial Officer. Mr. Geyen will report to Relievant’s Chief Executive Officer, Kevin Hykes.

“I am delighted to welcome Chris to the Relievant team. The addition of a seasoned financial executive is a key milestone in the company’s transition into a commercial organization ” said Kevin Hykes, President and Chief Executive Officer. “Over his career, Chris has been instrumental in driving financial strategy and rapid commercial growth. His extensive experience with successful public and private sector companies and strategic transactions will be invaluable to Relievant as the company enters its next phase of growth.”

Mr. Geyen brings 25 years of financial and executive leadership experience from the healthcare sector. He previously served as Chief Financial Officer of NeuWave Medical. After NeuWave’s acquisition by Johnson & Johnson in 2016, he continued on with J&J as a leader in the interventional oncology platform. Prior to NeuWave, Mr. Geyen served as CFO of Celleration where he helped guide the business through the process of securing reimbursement on its way to being acquired by Alliqua BioMedical. He also served as CFO of Restore Medical, where he completed an Initial Public Offering and subsequent acquisition by Medtronic, Acorn Cardiovascular, and Urologix. Mr. Geyen began his career with accounting firm EY (formerly Ernst & Young). Mr. Geyen holds a Bachelor of Arts in Business Administration and Accounting from the University of St. Thomas, Minnesota and is a licensed Certified Public Accountant (inactive).

About Relievant Medsystems
Founded in 2006 and based in Sunnyvale, California, Relievant Medsystems is a privately held medical device company developing new solutions to improve the quality of life for millions of patients suffering from CLBP.

Relievant’s Intracept® System delivers targeted energy into the spine and blocks the transmission of pain signals from the BVN. This minimally invasive procedure provides orthopedic surgeons, neurological surgeons and interventionalists with a new way to provide clinically proven, lasting pain relief for CLBP.

As with any surgical procedure, there are risks and considerations associated with the Intracept Procedure.  Please see for a discussion of the indications for use, risks, contraindications, warnings, precautions and a summary of the pivotal clinical trial data on the device.

Carrie Mendivil
Gilmartin Group